# Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age

> **NCT03563222** · PHASE4 · TERMINATED · sponsor: **Fresenius Kabi** · enrollment: 1 (actual)

## Conditions studied

- Malnutrition, Child

## Interventions

- **DRUG:** Smoflipid
- **DRUG:** Intralipid, 20%

## Key facts

- **NCT ID:** NCT03563222
- **Lead sponsor:** Fresenius Kabi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-18
- **Primary completion:** 2020-11-12
- **Final completion:** 2022-07-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Prematurely stopped in agreement with authorities (FDA)
- **Last updated:** 2022-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03563222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03563222, "Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03563222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*